Biogen to Buy Apellis Pharmaceuticals for 5.6 Billion
Biogen announced on Tuesday that it has agreed to acquire Apellis Pharmaceuticals for 5.6 billion dollars. The all-cash deal was confirmed by the company.
Xurve View
Insights:
Xurve View
Biogen Inc. has reached an agreement to acquire Apellis Pharmaceuticals, Inc. for approximately $5.6 billion. The biotechnology company announced the deal on Tuesday, confirming that the transaction will be conducted entirely in cash.
